It does look good for Prana's MPAC technology. Lack of progress...

It does look good for Prana's MPAC technology. Lack of progress since 2005. Where have you been? In 2005 Prana had only phase1 PBT2 trials done. Since then they have completed the P2 euro trial with good signals in executive function and CSF AB42 levels. In 2009 a post hoc analysis of the trial using a ranking analysis identified some great cognition results and it was published in 2010. Prana survived the global financial meltdown which peaked in 2008 as the euro results were released. Somehow management got Prana through that crisis and came out of it running two clinical trials in Australia and the USA, one out to 2 years. Two other small trials for PBT2 with food and caffine were run. Prior to IMAGINE and Reach2HD starting, Prana indicated they would take PBT2 to market through Huntington's disease. That is still on track. Remember the next trial should be a registration trial.

"(except for their testing of clioquinol)" Yea right, [The investigated compounds, particularly clioquinol, attenuated the increased expression of calpain] It seems CQ was the most effective, and that looks very good for Prana's CQ analogs. That abstract is very recent work on 8-hydroxyquinolines(MPACs) and is very relevant to this company, which owns some very promising brain cancer IP.